Autosomal-Recessive Limb-Girdle Muscular Dystrophy Caused by FKRP Mutations

Autosomal-recessive limb-girdle muscular dystrophy caused by FKRP mutations is a genetic muscle disease. It weakens the muscles around the hips, thighs, shoulders, and upper arms (the “limb girdles”). It happens when a child inherits two non-working copies of the FKRP gene—one from each parent. FKRP makes an enzyme that helps put special sugar units onto a muscle-surface protein called α-dystroglycan. These sugar units act like glue, holding the muscle cell to its support frame. When FKRP does not work well, the glue is weak. Muscle cells are easily damaged and slowly replaced by scar and fat. This causes progressive weakness, trouble walking, and sometimes heart and breathing problems. curecmd+3Muscular Dystrophy UK+3PMC+3

FKRP is a ribitol-5-phosphate transferase that helps attach ribitol-phosphate to the sugar chain on α-dystroglycan. Those sugar chains let α-dystroglycan bind the extracellular matrix. If FKRP fails, α-dystroglycan can’t anchor the muscle membrane properly, so everyday contractions cause micro-tears, inflammation, and gradual fiber loss. The same pathway explains why some people also get heart and occasionally brain involvement across the FKRP spectrum. NCBI+1

FKRP-related limb-girdle muscular dystrophy is a genetic muscle disease you inherit from both parents (autosomal-recessive). It mainly weakens the big muscles around the hips and shoulders (“limb-girdle” areas). The FKRP gene makes an enzyme that helps add special sugar tags (ribitol-phosphate) to a muscle-anchoring protein called α-dystroglycan. When FKRP is faulty, α-dystroglycan is under-glycosylated and the muscle cell membrane becomes fragile. Over time, muscle fibers are damaged and replaced by scar and fat, causing slowly progressive weakness; some people also develop heart muscle disease and breathing problems. Names you may see: LGMDR9 (formerly LGMD2I), FKRP-related dystroglycanopathy, MDDGC5 (older nomenclature). PMC+2Muscular Dystrophy UK+2

FKRP belongs to a family of “dystroglycanopathy” genes. FKRP’s job includes transferring ribitol-phosphate during the sugar-building steps on α-dystroglycan. This specific chemical step is important for the protein to grab on to the outside matrix and protect the muscle membrane. NCBI

Other names

• LGMDR9 FKRP-related (current name; “R” means recessive).

• LGMD2I (older name you will still see in reports and papers).

• FKRP-related dystroglycanopathy (umbrella term that links this LGMD to the glycosylation pathway).

• MDC1C (congenital—much earlier-onset—end of the same FKRP spectrum). Muscular Dystrophy UK+2European Reference Network+2

Types

Doctors think of FKRP disease as a spectrum, based mostly on the age when symptoms start and how fast they progress:

1. Typical LGMDR9 (childhood to teenage onset): Hip and thigh weakness often begins between ages 10–20. Calf muscles can look big. Walking worsens over years. Some people later get heart weakness or breathing problems. Muscular Dystrophy UK

2. Milder, adult-onset LGMDR9: Symptoms may start slowly in the 20s–40s and progress more gradually. Muscular Dystrophy UK

3. Congenital FKRP muscular dystrophy (MDC1C): Weakness starts in infancy with delayed motor milestones; brain or eye involvement can occur in the severest forms. These congenital cases share the same gene but represent the most severe end. NCBI

4. Cardiac-leading phenotype: In some people, heart muscle weakness (cardiomyopathy) appears and needs active monitoring and treatment. The chance and timing can vary with the exact FKRP variants. PMC+1

Causes

Because this is an autosomal-recessive disease, the main cause is always a harmful change in both copies of the FKRP gene. The list below breaks that down into the many ways this can happen or be influenced.

1. Biallelic FKRP mutations: Two damaging FKRP variants (one from each parent) cause the disease. Muscular Dystrophy UK

2. Missense variants: A single “letter change” that makes FKRP work less well (reduced enzyme activity). PMC

3. Nonsense or frameshift variants: Changes that shorten the FKRP protein so it cannot do its job. PMC

4. Splice-site variants: Changes that disrupt the way the FKRP message is cut and joined, producing faulty protein. PMC

5. Non-coding/promoter variants: Rare changes outside the protein code that lower FKRP levels. American Academy of Neurology

6. Compound heterozygosity: Two different FKRP mutations (one on each copy) together cause disease. Muscular Dystrophy UK

7. Founder variants in some populations: Certain FKRP changes are common in specific regions (for example, high frequency in Norway), raising disease rates there. PubMed

8. Defective α-dystroglycan glycosylation: The core disease mechanism—FKRP cannot add the right sugars, so the “glue” on muscle cells is weak. MedlinePlus+1

9. Ribitol-phosphate transfer defect: FKRP normally transfers ribitol-phosphate during glycosylation; losing this step breaks α-dystroglycan’s function. NCBI

10. CDP-ribitol pathway influence: Pathway partners (e.g., ISPD) supply the sugar donor; problems here can modify the FKRP phenotype. NCBI

11. Golgi mis-processing: FKRP works in the Golgi apparatus; gene defects derail this processing hub. MedlinePlus

12. Low residual FKRP activity: Some variants leave a little activity and cause milder, later disease; very low activity leads to earlier, more severe disease. Orpha

13. Population genetics (carriers): In communities with many carriers or consanguinity, two carriers are more likely to have an affected child. Muscular Dystrophy UK

14. Genotype-cardiac links: Certain FKRP genotypes carry different risks for heart weakness and at different ages. PMC

15. Muscle membrane fragility: Poorly glycosylated α-dystroglycan cannot anchor well; repeated use injuries the membrane, driving weakness. curecmd

16. Spectrum overlap with congenital forms: The same gene can cause infant or later-onset disease depending on variants and activity left. NCBI

17. Modifier genes in the pathway: Other glycosylation genes (e.g., FKTN, POMT1/2) may modify severity across dystroglycanopathies. curecmd

18. Founder clustering of specific variants: Regional clusters (e.g., c.826C>A) shift local prevalence and typical age at heart involvement. PMC+1

19. Biochemical bottleneck (ribitol availability): Experimental work shows ribitol supply can affect α-dystroglycan glycosylation in FKRP disease models. Nature

20. Inheritance risk across generations: Parents with one FKRP change (carriers) are healthy but have a 25% risk per pregnancy if both are carriers. Muscular Dystrophy UK

Symptoms and signs

1. Trouble running, jumping, or climbing stairs: Early hip/thigh weakness makes these tasks hard. Muscular Dystrophy UK

2. Difficulty rising from the floor (Gowers’ pattern): Children/teens may “climb up” their thighs to stand. Medscape

3. Walking changes and frequent falls: Gait becomes wobbly or waddling as hip muscles weaken. Muscular Dystrophy UK

4. Big-looking calves (calf hypertrophy): Calves enlarge with fat/scar replacement, especially early. Muscular Dystrophy UK

5. Shoulder and arm weakness: Lifting arms overhead or carrying objects becomes difficult. Muscular Dystrophy UK

6. Scapular winging: Shoulder blades stick out because stabilizing muscles weaken. Muscular Dystrophy UK

7. Muscle pain after exercise and easy fatigue: Damaged fibers ache and tire quickly. Muscular Dystrophy UK

8. Stiff joints (contractures): Ankles, knees, or elbows may tighten over time. Muscular Dystrophy UK

9. Breathing problems at night (sleep-related hypoventilation): Morning headaches, daytime sleepiness, or frequent chest infections can appear. Muscular Dystrophy UK

10. Shortness of breath on exertion: Respiratory muscles weaken, especially later in the course. Muscular Dystrophy UK

11. Heart muscle weakness (cardiomyopathy): Breathlessness, tiredness, or reduced heart pump function on tests. PMC

12. Slowly progressive course over years: Rate varies by person and by genotype. Muscular Dystrophy UK

13. Occasional macroglossia (large tongue) or abdominal weakness: Less common but reported. Muscular Dystrophy UK

14. Later wheelchair use in some: Especially with earlier onset or faster progression. Muscular Dystrophy UK

15. Normal intelligence in LGMD forms: Brain involvement is typical only at the severe congenital end of the FKRP spectrum. NCBI

Diagnostic tests

A) Physical examination

1. Pattern of proximal weakness: Doctor checks hip/thigh and shoulder/arm strength; LGMD patterns point toward a limb-girdle disease. Muscular Dystrophy Association

2. Gowers’ maneuver: Watching how you rise from sitting or the floor helps show hip weakness. Medscape

3. Calf size and muscle bulk: Large calves or thinning thigh muscles are important clues. Muscular Dystrophy UK

4. Posture and gait analysis: Waddling gait, toe-walking, or lordosis may be seen. Medscape

5. Joint range and contractures: Simple bedside checks of ankle/knee/shoulder tightness guide therapy needs. Muscular Dystrophy UK

B) Manual/functional bedside tests

6. Manual muscle testing (MRC grading): A hands-on 0–5 scale rates strength and tracks change over time. Medscape

7. Timed up-and-go / 10-meter walk: Short timed tasks measure speed and stability and are easy to repeat in clinic. Medscape

8. Sit-to-stand (30-second or 5-repetition): Simple test of hip and thigh power. Medscape

9. Six-minute walk test: Shows endurance and correlates with daily function. Medscape

10. Peak cough flow at bedside: Quick measure of cough strength to flag respiratory support needs. Muscular Dystrophy UK

C) Laboratory & pathological tests

11. Blood creatine kinase (CK): Usually elevated and a common first clue to a muscle-damage disorder. Muscular Dystrophy UK

12. Next-generation sequencing panel: A blood test that reads many LGMD genes—including FKRP—to confirm the exact genetic cause. Mayo Clinic Laboratories

13. Targeted FKRP testing / family studies: Once a family variant is known, quick targeted tests can confirm relatives. BlueShieldCA

14. Muscle biopsy (histology): Shows chronic “dystrophic” changes (fiber size differences, scar/fat). Useful if genetics is unclear. Muscular Dystrophy Association

15. Immunohistochemistry or western blot for α-dystroglycan: Demonstrates hypoglycosylation (weaker staining/band) typical of FKRP pathway disease. curecmd

D) Electrodiagnostic & cardiopulmonary tests

16. Electromyography (EMG): Shows a myopathic pattern (small, brief motor units) without nerve damage. Muscular Dystrophy UK

17. Electrocardiogram (ECG) and Holter: Screens for rhythm problems when the heart is involved. PMC

18. Spirometry (FVC sitting and supine): Measures breathing muscle strength; falling supine FVC suggests diaphragm weakness. Muscular Dystrophy UK

E) Imaging tests

19. Muscle MRI (thigh/calf): Often shows characteristic patterns of fatty change in thigh and calf muscles that support an LGMD diagnosis and help rule in/out other subtypes. PMC+1

20. Cardiac imaging: Periodic echocardiogram and sometimes cardiac MRI to detect cardiomyopathy early and guide treatment. PMC

Non-pharmacological treatments

There’s no approved disease-modifying drug yet for FKRP-LGMD. Care focuses on structured rehab, cardiac and respiratory prevention, nutrition, safety, and genetic counseling. (I reference LGMD care guidance, CHEST/respiratory, and CDC where relevant.)

1. Individualized physiotherapy & energy-conserving activity: gentle, regular movement to keep joints flexible and muscles conditioned; avoid painful over-exertion and heavy eccentric loading; consider water-based exercise. Purpose: preserve mobility; Mechanism: maintain range/strength without fiber damage. Muscular Dystrophy Association+1

2. Daily stretching & night splints for Achilles/hamstrings to delay contractures and maintain gait. PMC

3. Submaximal aerobic training (e.g., cycling, swimming) with rest breaks; start early, monitor heart/respiratory status. Parent Project Muscular Dystrophy

4. Occupational therapy for task adaptation, safe transfers, bathroom and kitchen modifications; powered mobility timing. PMC

5. Ankle-foot orthoses & stance control bracing to stabilize gait and reduce falls; reassess as weakness progresses. PMC

6. Falls program & home safety (lighting, rails, shower chair); reduces injury risk. PMC

7. Respiratory physiotherapy: assisted cough devices, lung-volume recruitment, breath-stacking, and vaccinations to reduce infections. Chest Journal+1

8. Non-invasive ventilation (NIV) at night when FVC declines or there’s nocturnal hypoventilation—improves sleep and survival. Chest Journal

9. Speech/swallow therapy if bulbar issues; textures and pacing to prevent aspiration. Chest Journal

10. Cardiac surveillance yearly (ECG/echo; earlier if symptoms) with referral to cardiology experienced in neuromuscular disease. AHA Journals

11. Nutritional counseling to maintain healthy weight; avoid sarcopenic under-nutrition and steroid-like weight gain patterns. PMC

12. Bone health strategy: safe vitamin D/calcium intake, weight-bearing as tolerated, fall prevention. PMC

13. Pain management without over-sedation (heat, pacing, cautious analgesics), because respiratory reserve may be limited. Chest Journal

14. Psychological support & peer groups for coping, adherence, and family stress. PMC

15. Vaccinations: annual influenza; pneumococcal per CDC risk-based guidance. CDC+1

16. Pre-operative planning: anesthesia teams should know the genetic subtype; major surgery where ICU backup exists. LGMD Awareness Foundation

17. Therapy break rules: pause/scale activity during acute illness/exacerbations to avoid deconditioning spirals. PMC

18. School/work accommodations: rest breaks, elevator access, ergonomic seating; improves participation. PMC

19. Genetic counseling for family testing, carrier status, and reproductive planning (PGT, prenatal options). Muscular Dystrophy Association

20. Clinical-trial awareness/registries (e.g., Global FKRP Registry) to access emerging therapies. National Organization for Rare Disorders

---

Drug treatments

There is no FDA-approved drug specifically for FKRP-LGMD as of today. Drug therapy is symptom- and complication-directed, especially for heart failure (when present) and allied issues. When I cite FDA, it’s to the official U.S. labeling for the underlying indication (e.g., HFrEF). Always prescribe via a cardiologist/neuromuscular specialist; doses below are label-typical ranges, not individualized advice.

Heart-failure disease-modifying foundation (if cardiomyopathy/HFrEF is present):

1. ACE inhibitor (lisinopril) – Class: ACEI. Typical dose range 5–40 mg once daily. Purpose: reduce afterload, remodel LV, improve survival. Mechanism: blocks angiotensin-II formation; Side effects: cough, hyperkalemia, fetal toxicity (boxed warning). FDA Access Data+1

2. ARNI (sacubitril/valsartan, ENTRESTO) – Class: neprilysin inhibitor + ARB. Start after ACEI washout. Purpose: superior morbidity/mortality benefit vs ACEI in HFrEF; Dosing per label; Side effects: hypotension, hyperkalemia, fetal toxicity. FDA Access Data+1

3. Beta-blocker (carvedilol) – Class: non-selective β/α1 blocker. Up-titrate (e.g., 3.125 mg bid → 25–50 mg bid). Purpose: mortality/morbidity reduction; Mechanism: blocks sympathetic drive; Side effects: bradycardia, hypotension. FDA Access Data+1

4. Alternatively: Beta-1 selective (metoprolol succinate, TOPROL-XL) – Extended-release; titrate to target for HFrEF. Side effects: bradycardia, fatigue; boxed warning re abrupt withdrawal. FDA Access Data+1

5. Mineralocorticoid receptor antagonist (eplerenone/INSPRA) – Purpose: survival benefit, fibrosis inhibition; Dosing per label; Side effects: hyperkalemia, especially with CKD. FDA Access Data

6. Alternative MRA (spironolactone/ALDACTONE or CAROSPIR) – Similar benefits; watch for hyperkalemia and endocrine effects. FDA Access Data+1

7. SGLT2 inhibitor (dapagliflozin/FARXIGA) – Indication includes HFrEF regardless of diabetes; Purpose: reduce CV death/HF hospitalization; Side effects: genital mycotic infection, volume depletion. FDA Access Data

8. SGLT2 inhibitor (empagliflozin/JARDIANCE) – Similar HFrEF benefits; dosing 10 mg daily typical. FDA Access Data

9. Ivabradine (CORLANOR) – For sinus rhythm LVEF≤35% with HR ≥70 bpm on max β-blocker or intolerance; Purpose: reduce HF hospitalization by If-channel blockade; Side effects: bradycardia, luminous phenomena. FDA Access Data+1

10. Loop diuretic (furosemide/LASIX) – Symptomatic relief of congestion; careful titration; Side effects: electrolyte losses. FDA Access Data

Additional commonly used, case-by-case (specialist supervision):

11. ARB if ACEI intolerant – (valsartan is part of ARNI; stand-alone ARB per label when ACEI not tolerated). FDA Access Data

12. Potassium binders (if hyperkalemia limits GDMT) — per HF practice; label-based use. (General FDA labeling basis.) FDA Access Data

13. Anti-arrhythmics/anticoagulation when indicated by rhythm/echo (e.g., AF with stroke risk, LV thrombus)—individualized and outside FKRP-specific evidence. (Use FDA-labeled products according to cardiology guidelines.) AHA Journals

14. Vaccines (influenza, pneumococcal) — not “drugs” but medication-class preventives that reduce respiratory decompensation risk. CDC+1

15. Bronchodilators are not routine unless there’s coexisting asthma/COPD; respiratory weakness is neuromuscular, not airway. (CHEST guideline emphasizes NMD-specific care.) Chest Journal

16. Analgesics for musculoskeletal pain — use the lowest effective dose; avoid sedating agents that could depress respiration. Chest Journal

17. Osteoporosis pharmacotherapy if clinically indicated (density loss/fractures)—per general bone health guidelines. PMC

18. Sleep-related breathing disorder therapies (NIV—not a drug) with adjuncts like mucolytics only if concurrent airway disease—specialist guided. Chest Journal

19. Edema control may require cautious diuretic combinations—specialist titration using FDA-labeled products. FDA Access Data

20. Clinical-trial medications: investigational gene therapy or small molecules—not FDA-approved; access only via trials/expanded access. U.S. Food and Drug Administration

---

Dietary molecular supplements

1. Creatine monohydrate – RCTs/Cochrane show small but meaningful strength gains in muscular dystrophies; typical study dosing 3–5 g/day after loading; mechanism: boosts phosphocreatine energy buffer. Monitor kidneys; avoid in those with contraindications. PMC+1

2. Coenzyme Q10 (ubiquinone) – Mixed evidence (small studies, mostly DMD) for strength or cardiac metrics; typical 100–300 mg/day in trials; mitochondrial electron transport support. Individualize; not FDA-approved for MD. PMC+1

3. Vitamin D3 – Supports bone health and muscle function; typical maintenance 800–1000 IU/day for adults, with higher doses short-term for deficiency—test and titrate. PMC+1

4. Calcium (diet first, then supplement if needed) – Bone mineral support; dose individualized by diet/age; excess can cause stones/constipation. Bone Health & Osteoporosis Foundation

5. Omega-3 fatty acids (fish oil) – Anti-inflammatory; limited direct MD evidence; general cardiovascular support—dose commonly 1–2 g EPA/DHA combined/day under clinician guidance. (General evidence base; not disease-specific.) AHA Journals

6. Protein optimization (whey/casein as needed) – Supports muscle maintenance; spread intake through the day; target per dietitian. (General nutrition guidance in NMD.) PMC

7. Antioxidant-rich foods (berries/greens) – Healthy pattern support; supplement pills show inconsistent benefits; prioritize whole foods. (General guidance.) PMC

8. Magnesium (if deficient) – May help cramps; avoid excess causing diarrhea or affecting kidneys. (General clinical guidance.) PMC

9. Caffeine timing – Can improve perceived exertion but may raise heart rate; avoid late-day use in those with cardiomyopathy. (General evidence.) AHA Journals

10. Multivitamin – Backstop for marginal intake; choose modest-dose products; avoid mega-doses. (General guidance.) PMC

---

Immunity-booster / Regenerative / Stem-cell drugs

Important safety note. There are no FDA-approved stem-cell or “regenerative” drugs for FKRP-LGMD. The FDA repeatedly warns patients to avoid unapproved stem-cell/exosome clinics because of serious harms (blindness, infections, tumors). If you see advertising for stem cells to treat muscular dystrophy, that’s not FDA-approved care. Participation should only occur in legitimate clinical trials under FDA oversight. U.S. Food and Drug Administration+1

1. Non-invasive ventilation (device therapy, not a drug) – best-evidence “regenerative”-adjacent support by preventing chronic CO₂ retention and downstream organ stress. Chest Journal

2. Structured aerobic/strength-sparring rehab – promotes mitochondrial biogenesis and slows deconditioning. Parent Project Muscular Dystrophy

3. Cardiorenal-protective HF drugs (ACEI/ARNI/β-blocker/SGLT2/MRA) – prevent “secondary damage” to heart muscle (true disease-modifying in HFrEF). FDA Access Data+1

4. Clinical-trial gene therapy (AAV-FKRP/others) – Investigational only at present; consider via registries. National Organization for Rare Disorders

5. Vaccination program – decreases infection-triggered deterioration; essential in NMD. CDC

6. Bone-health care (Vit D/calcium, fall prevention) – protects function reserve; not curative but crucial. PMC

---

Surgeries

1. Tendon-lengthening (e.g., Achilles) / contracture release to improve foot placement, reduce falls, and ease bracing. PMC

2. Spinal fusion if progressive scoliosis impairs sitting balance or lung function. PMC

3. Upper-limb tendon transfers (selected cases) to improve reach/self-care when specific muscle groups fail. PMC

4. Cardiac device therapy (ICD/CRT) for arrhythmia or dyssynchrony in cardiomyopathy. Heart Rhythm Journal

5. Heart transplantation in rare advanced cardiomyopathy despite optimal therapy. Orpha

---

Prevention & risk-reduction

1. Confirm the genetic diagnosis and subtype early;

2. annual cardiology and pulmonary reviews;

3. vaccinations (influenza and pneumococcal per CDC);

4. regular stretching and gentle activity;

5. home fall-proofing;

6. nutrition to keep a healthy weight;

7. vitamin D sufficiency;

8. travel/surgery planning with an LGMD “alert card”;

9. avoid unregulated “stem-cell” clinics;

10. genetic counseling for family planning. LGMD Awareness Foundation+2CDC+2

---

When to see a doctor

New/worsening shortness of breath, morning headaches or poor sleep, chest pain, palpitations, fainting, rapid swelling/weight gain, repeated chest infections or weak cough, increasing falls or contractures, sudden functional drops, or any plan for anesthesia/surgery. These warrant neuromuscular, cardiology, and pulmonary assessment promptly. Chest Journal+1

---

What to eat / what to avoid

Eat more of: protein-rich meals spaced through the day; fruits/vegetables (antioxidants); whole grains; omega-3-rich fish; adequate fluids; calcium- and vitamin-D–containing foods. Limit/avoid: crash diets (muscle loss), excessive salt (if heart failure/edema), very late caffeine (sleep, heart rate), alcohol excess (myopathy risk), and unregulated supplements promising “cures.” Tailor with a dietitian if underweight/overweight or if heart failure fluid limits apply. PMC

---

FAQs

1. Is there a cure yet? Not yet; care focuses on heart/lung protection, rehab, and safety; gene-targeted trials are in progress. National Organization for Rare Disorders

2. Is it contagious? No—purely genetic.

3. Can exercise help or harm? Gentle, submaximal activity helps; avoid heavy eccentric/over-fatiguing exercise. Parent Project Muscular Dystrophy

4. Will I need a wheelchair? Many people eventually use mobility aids—timing varies widely by person. NMD Journal

5. Do I need heart checks if I feel fine? Yes—yearly or per specialist, because cardiomyopathy can be silent early. PMC

6. What about breathing at night? Screening PFTs and sleep assessments catch problems early; NIV helps when needed. Chest Journal

7. Are steroids used like in DMD? No routine role in FKRP-LGMD; management differs from dystrophinopathies. PMC

8. Which supplements are worth considering? Creatine has the best supportive evidence in MD; others are case-by-case. PMC

9. Can diet stop progression? Diet can’t cure it but supports muscle, bone, weight, and cardiac health. PMC

10. Is pregnancy safe? Needs pre-conception counseling and cardio-pulmonary planning; involve high-risk obstetrics. Muscular Dystrophy Association

11. Are stem-cell shots from clinics safe? No—these are unapproved and risky; avoid outside trials. U.S. Food and Drug Administration

12. How do I find trials? Use the Global FKRP Registry and ClinicalTrials.gov filters for LGMDR9. National Organization for Rare Disorders+1

13. Should I get flu and pneumonia shots? Yes, per CDC—these reduce respiratory complications. CDC+1

14. Can children be tested? Genetic testing confirms the subtype and guides surveillance; counsel first. Muscular Dystrophy Association

15. Are heart-failure drugs really needed if I’m “just a bit tired”? If cardiomyopathy is present, guideline-directed meds improve outcomes even when symptoms are mild. FDA Access Data+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 09, 2025.

PDF Documents For This Disease Condition References